Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Inflammatory, Functional and Image Composite Measure to Define Asthma Control (APITA)

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified November 2007 by Federal University of São Paulo.
Recruitment status was:  Recruiting
Fundação de Amparo à Pesquisa do Estado de São Paulo
Information provided by:
Federal University of São Paulo Identifier:
First received: January 8, 2008
Last updated: January 16, 2008
Last verified: November 2007
The goals of control status of asthma have been changed with the improvement of its management as a chronic disease; many steps should be taken to achieve asthma control as defined by the GINA/NIH guidelines. There are good results with single variables, but overall asthma control should be addressed in different ways. Most traditional clinical studies provide an incomplete assessment of disease control, despite good clinical practice. The association of inhaled corticosteroid (IC) and long-action beta 2 agonist (LABA) has already showed their efficacy to reduce asthma symptoms, exacerbations and cost for moderate and severe asthma patients as well as the improvement in their quality of life. On the other hand, even with the use of first line maintenance medication, as recommended by guidelines, some asthmatic patients fail in obtaining a total control of the disease. This lack of efficacy, led us to hypothesize, that these patients who fail in response, would present chronic and fixed airway obstruction as a consequence of persistent inflammation and airway remodeling. This study has the purpose of looking for an adequate composite measure to provide an indicator of overall asthma status more accurately and meaningfully as reflect of treatment effectiveness and disease control. For this, we will test by a randomized control trial if an additional oral corticosteroid treatment could modify spirometric and plethysmography values, nasal and low airway cytology and HRCT (to evaluate small airway) in regularly treated stable asthma patients who have a positive bronchodilator response.

Condition Intervention Phase
Drug: prednisone
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Inflammatory, Functional and Image Composite Measure to Define Asthma Control

Resource links provided by NLM:

Further study details as provided by Federal University of São Paulo:

Primary Outcome Measures:
  • Asthma control status characterized by nocturnal and diurnal symptom score FEV1,total lung capacity in plethysmography and reducing the air-tapping in HRCT. [ Time Frame: 30 days ]

Secondary Outcome Measures:
  • Quality of life, Sputum and nasal cytology, adverse events [ Time Frame: 30 days ]

Estimated Enrollment: 70
Study Start Date: July 2006
Estimated Study Completion Date: March 2008
Estimated Primary Completion Date: March 2008 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: prednisone
    oral prednisone 40 mg/day for 15 +/- 5 days
    Other Name: prednisone or placebo radom assigned
Detailed Description:

To evaluate the achievement of asthma control status in asthmatic patients, regularly treated with IC + LABA to answer the following questions:

i. Is it possible to improve the pulmonary function (spirometry and plethysmography) of stable asthma patients, regularly treated with IC + LABA, who have a positive bronchodilator response, with the introduction of oral steroid?

ii. What is the relationship among nasal, induced sputum and blood cytology, as a tool to observe inflammatory airway expression, in controlled and total controlled asthma patients? What will be these values response if oral steroids have been introduced?

iii. What is the correlation between pulmonary volumes and airways inflammation to evaluate severity and control status in asthmatic patients, using plethysmography and HRCT? What will be these values response if oral steroids have been introduced?


Ages Eligible for Study:   16 Years to 80 Years   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion criteria:

  • A documented clinical asthma history at least for a period of six months
  • Regular treatment (IC + LABA) at least for a period of three months
  • Controlled symptoms score defined by GINA 2002 criteria (daytime symptoms < 2 days a week and no night time symptoms in the last 15 days) or complete absence of chronic symptoms
  • None or minimal exacerbations without emergency visits
  • Absent or a minimal usage bronchodilator rescue, side effects of medication and limitation to exercises
  • Documented airway reversibility of 200 ml and 7% based on predicted values of VEF1

Exclusion Criteria:

  • Having a smoking history of 5 pack/years or more; having other known chronic pulmonary diseases; having side effect to oral corticosteroid
  • Having an upper or lower respiratory tract infection within 4 weeks of visit 0
  • Unable to do the tests involved in the study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00597064

Contact: Ana Luisa G Fernandes, MD, PhD 551150841268
Contact: Maria Marta F Amorim, MSc 55 11 50841268

Rua Botucatu 740 3 ° and - Pneumologia Recruiting
São Paulo, Sao Paulo, Brazil, 04023062
Contact: Maria Marta F Amorim, MSc    55 11 50841268   
Contact: Patricia B Lima, Techinician    55 11 50841268   
Principal Investigator: Ana Luisa G Fernandes, MD, PhD         
Sub-Investigator: Alexander Araruna, MD         
Sub-Investigator: Maria Marta F Amorim, MSc         
Sponsors and Collaborators
Federal University of São Paulo
Fundação de Amparo à Pesquisa do Estado de São Paulo
Principal Investigator: Ana Luisa G Fernandes, MD, PhD Federal University of Sao Paulo
  More Information

Additional Information:
Responsible Party: Ana Luisa Godoy Fernandes, Federal University of Sao Paulo- Respiratory Division Identifier: NCT00597064     History of Changes
Other Study ID Numbers: APITA
Study First Received: January 8, 2008
Last Updated: January 16, 2008

Keywords provided by Federal University of São Paulo:
asthma control questionnaire
oral corticosteroid
air trapping
quality of life

Additional relevant MeSH terms:
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Immune System Diseases
Anti-Inflammatory Agents
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Antineoplastic Agents, Hormonal
Antineoplastic Agents processed this record on May 22, 2017